Sutro Biopharma, Inc. (STRO) Tops Q3 EPS by 14c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.59), $0.14 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $15.29 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• argenx SE (ARGX) PT Raised to $1,200 at Citizens on VYVGART Indication Expansion
• Infleqtion raises Q2 revenue to $13.5M after contract restatement